Author

Ana Almonte

Observed names: A Almonte, A. Almonte

Institution: Institut Gustave Roussy

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Dartmouth–Hitchcock Medical Center, Brooklyn Hospital Center, The University of Texas at San Antonio Health Science Center, Columbia University Irving Medical Center, Institut Gustave Roussy, Dana-Farber Cancer Institute, Rocky Mountain Cancer Centers, Eisai (United Kingdom), Eisai (United States)

OpenAlex ID: A5047788825

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

2021 · Lori J. Wirth, Marcia S. Brose, et al. · Journal of Clinical Oncology · 128

Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

2018 · SM Tolaney, K Kalinsky, et al. · Cancer Research · 71

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

2017 · S. Tolaney, C. Savulsky, et al. · European Journal of Cancer · 42

Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

2017 · S Tolaney, C Savulsky, et al. · Cancer Research · 14

Phase II Study of Eribulin Mesylate Administered Biweekly in Patients With Human Epidermal Growth Factor Receptor-2–negative Metastatic Breast Cancer

2019 · John Smith, Amy Irwin, et al. · Clinical Breast Cancer · 7

34.36 Extracardiac lesions: Why more prominent on the rest SPECT?

2005 · I. Seo, E. Del Priore, et al. · Journal of Nuclear Cardiology · 6

MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)

2020 · Lori J Wirth, Marcia S Brose, et al. · Journal of the Endocrine Society · 4

Abstract OT1-03-19: Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer

2016 · E Berrak, G Atkan, et al. · Cancer Research · 2

116P Multiomic profiling based on Akkermansia muciniphila in advanced non-small cell lung cancer

2024 · L. Belluomini, A. Bonato, et al. · ESMO Open

Abstract OT2-02-02: A randomized, open-label, multicenter, phase 1b/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2-negative, high-hyaluronan metastatic breast cancer

2017 · RH Alvarez, C Savulsky, et al. · Cancer Research

Works count: 10

Citation count: 274

H-index: 6

I10-index: 4